DEC 1 8 2006

I hereby certify the Trespondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313 on the date shown below:

IFW Receipt

Patent Application Docket No. SPO-126 Serial No. 10/577,612

December

11 2006

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants** 

Hiroshi Tsuboi et al.

Serial No.

10/577,612

Conf. No.

5366

Filed

April 28, 2006

For

α-Glucosidase Activity Inhibitors (as amended)

Office of Initial Patent Examination Customer Service Center Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

## REQUEST FOR CORRECTION OF FILING RECEIPT

Sir:

The applicants respectfully request the correction of error in the official Filing Receipt for the above-identified patent application. A clerical error has occurred in the title of the application. The correction needed is as follows:

Title

Alpha-glucosidase activity inhibitor

should read

Alpha-glucosidase activity inhibitors

Please note that the title of the subject application was amended by Preliminary Amendment filed April 28, 2006, copy attached. Also attached is a copy of the erroneous Filing Receipt marked-up to indicate the correction needed. Correction of the above is respectfully requested.

Respectfully submitted,

David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Address: 2421 N.W. 41st Street, Suite A-1


avid Saliwanchik

Gainesville, FL 32606-6669

DRS/la

Enclosures: Copy of erroneous Filing Receipt;


Copy of Preliminary Amendment filed April 28, 2006



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Dox 1450 Alexandria, Viginia 22313-1450 www.nspto.gov

FILING OR 371 FIL FEE REC'D ATTY.DOCKET NO DRAWINGS TOT CLMS IND CLMS ART UNIT APPL NO. (c) DATE 3 1030 SPO-126 1614 10/577.612 10/02/2006

23557 SALIWANCHIK LLOYD & SALIWANCHIK A PROFESSIONAL ASSOCIATION PO BOX 142950 GAINESVILLE, FL 32614-2950



Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)

Hiroshi Tsuboi, Kanagawa, JAPAN; Shuji Ikegami, Kanagawa, JAPAN; Zai-si Ji, Kanagawa, JAPAN; Hiroyuki Itou, Kanagawa, JAPAN; Munehiro Oda, Kanagawa, JAPAN; Kazuo Shin, Kanagawa, JAPAN;



Power of Attorney: The patent practitioners associated with Customer Number 23557.

#### Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP04/16333 11/04/2004

### Foreign Applications

JAPAN 2003-374837 11/04/2003

If Required, Foreign Filing License Granted: 11/03/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/577,612

Projected Publication Date: 02/15/2007

Non-Publication Request: No

Early Publication Request: No

Title

Alpha-glucosidase activity inhibitor §

**Preliminary Class** 

514

## PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "too!kits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The

ď

date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

DEC 18 2006 W

Patent Application Preliminary Amendment Docket No. SPO-126

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) :

Hiroshi Tsuboi, Shuji Ikegami, Zai-si Ji, Hiroyuki Itou, Munehiro Oda,

Kazuo Shin

Docket No.

SPO-126

For

 $\alpha$ -GLUCOSIDASE ACTIVITY INHIBITOR

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



## PRELIMINARY AMENDMENT

This application is a National Stage Application of International Application Number PCT/JP2004/016333. Please amend the above-identified patent application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims following the specification amendments.

Remarks/Arguments follow the amendment sections of this paper.

# In the Specification

# Please amend the title of the International Patent Application to read as follows:

## α-GLUCOSIDASE ACTIVITY INHIBITOR INHIBITORS

# Please add the following paragraph at page 1, above line 5 after the Title:

This application is a National Stage Application of International Application Number PCT/JP2004/016333, filed November 4, 2004; which claims priority to JP 2003-374837, filed November 4, 2003.

## In the claims

The following amendments are made with respect to the claims in the international application PCT/JP2004/016333.

This listing of claims will replace all prior versions and listings of claims in this application.

- 1 (original). An  $\alpha$ -glucosidase activity inhibitor comprising a *Nelumbonaceae* plant preparation.
- 2 (currently amended). A pharmaceutical composition for treating or preventing diabetes, wherein the composition comprises the  $\alpha$ -glucosidase inhibitor of claim 1 an  $\alpha$ -glucosidase activity inhibitor comprising a *Nelumbonaceae* plant preparation.
- 3 (currently amended). A food composition for treating or preventing diabetes, wherein the composition comprises the  $\alpha$  glucosidase activity inhibitor of claim 1 an  $\alpha$ -glucosidase activity inhibitor comprising a *Nelumbonaceae* plant preparation.

### Remarks

This application is a National Stage Application of International Application Number PCT/JP2004/016333. By this amendment, the title has been amended to correct the title of the PCT publication, which fails to accurately reflect the claimed invention. Also, the specification has been amended to include a "Cross-Reference Section." No new matter has been added by these amendments.

Claims 1-3 are pending in the subject international patent application. By this Amendment, claims 2 and 3 have been amended. No new matter has been added by these amendments. Accordingly, claims 1-3 are before the Examiner for consideration.

Please note that a complete translation of the subject application is also attached with this Preliminary Amendment.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§§1.16, 1.17, or 1.492 as required by this paper to Deposit Account No. 19-0065.

Respectfully Submitted,

David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.:

352-375-8100

Address:

Saliwanchik, Lloyd & Saliwanchik

P.O. Box 142950

Gainesville, FL 32614-2950

DRS/la

Attachment: English translation of PCT/JP2004/016333